Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet, Canagliflozin, Flash Glucose Monitoring (FGM)
Eligibility Criteria
Inclusion Criteria: Volunteer to participate and be able to sign informed consent prior to the trial. Patients with type 2 diabetes, aged 18-75 years old and BMI ≥18.0kg/m2. Treatment with one or two hypoglycemic drugs (in combination, the sulfonylureas dose should be less than half of the maximum dose). HbA1c : 7.0-9.0%. Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise. Exclusion Criteria: Impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value; Serum creatinine was 1.3 times higher than the upper limit of normal. Recurrent urinary tract infections. Drug abuse and alcohol dependence in the past 5 years. Patients with poor compliance and irregular diet and exercise. Systemic hormone therapy was used in the last three months. Patients with infection and stress within four weeks. Patients with pregnancy, lactation or pregnancy intention. Any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
Sites / Locations
- Jianhua Ma
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Mulberry Twig Alkaloid Tablet
Canagliflozin
Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet
Canagliflozin